{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T05:46:33Z","timestamp":1782279993451,"version":"3.54.5"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:00:00Z","timestamp":1782259200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aimed to compare the efficacies of conbercept and ranibizumab for the treatment of idiopathic choroidal neovascularization (ICNV) using optical coherence tomography angiography (OCTA) and multifocal electroretinography (mfERG).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Sixty patients with ICNV were retrospectively assessed and followed up in this retrospective comparative cohort study. Thirty patients were assigned to the conbercept group, and 30 patients were assigned to the ranibizumab group. Patients in both groups were treated with 1+ pro re nata. Best-corrected visual acuity (BCVA), macular central retinal thickness (CRT), and CNV blood flow area before treatment and at 1, 3, 6, and 12 months after treatment were obtained. The first positive peak (P1) amplitude density in ring 1 and intraocular pressure (IOP) were recorded at baseline and the last follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The follow-up duration was 12 months. BCVA (logMAR) improved at 1, 3, 6, and 12 months after the injection, and the CRT and CNV blood flow area significantly decreased in both groups relative to their values before treatment (p &amp;lt; 0.05). The P1 amplitude densities in ring 1\u00a0at baseline were 50.97 \u00b1 8.05 nv\/deg\n                      <jats:sup>2<\/jats:sup>\n                      and 52.50 \u00b1 9.71 nv\/deg\n                      <jats:sup>2<\/jats:sup>\n                      in the conbercept and ranibizumab groups, respectively (p = 0.5080). The change in the P1 amplitude density from baseline to the last follow-up visit was statistically significant (p &amp;lt; 0.05) in both groups. No significant changes were noted in the BCVA, IOP, CRT, CNV blood flow area, and P1 amplitude density after treatment from the baseline for the two groups. The number of injections was 2.00 \u00b1 1.05 for the conbercept group and 2.67 \u00b1 1.06 for the ranibizumab group (p = 0.0077). No serious ocular complications such as endophthalmitis and systemic adverse reactions such as myocardial infarction or cerebral infarction occurred in both groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Compared with intravitreal ranibizumab, intravitreal conbercept had a similar therapeutic effect in improving the structure and function on ICNV but with fewer injections.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1854440","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T04:49:25Z","timestamp":1782276565000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparison of conbercept and ranibizumab for the treatment of idiopathic choroidal neovascularization using optical coherence tomography angiography and multifocal electroretinography"],"prefix":"10.3389","volume":"17","author":[{"given":"Gaixia","family":"Zhai","sequence":"first","affiliation":[{"name":"Zibo Central Hospital","place":["Zibo, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Zhu","sequence":"additional","affiliation":[{"name":"Zibo Central Hospital","place":["Zibo, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanzhen","family":"Su","sequence":"additional","affiliation":[{"name":"Zibo Central Hospital","place":["Zibo, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuofen","family":"Wang","sequence":"additional","affiliation":[{"name":"Zibo Central Hospital","place":["Zibo, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1159\/000492133","article-title":"Etiologies and characteristics of choroidal neovascularization in young Chinese patients","volume":"241","author":"Bing","year":"2018","journal-title":"Ophthalmologica"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1080\/02713683.2020.1742357","article-title":"The evaluation of a two-year outcome of intravitreal conbercept versus ranibizumab for pathological myopic choroidal neovascularization","volume":"45","author":"Chen","year":"2020","journal-title":"Curr. Eye Res."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.2147\/IJN.S126865","article-title":"Topical ocular delivery to laser-induced choroidal neovascularization by dual internalizing RGD and TAT peptide-modified nanoparticles","volume":"12","author":"Chu","year":"2017","journal-title":"Int. J. Nanomedicine"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1016\/s0161-6420(96)30515-0","article-title":"Etiology of choroidal neovascularization in young patients","volume":"103","author":"Cohen","year":"1996","journal-title":"Ophthalmology"},{"key":"B5","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1097\/01.opx.0000216019.88256.eb","article-title":"Vision loss in younger patients: a review of choroidal neovascularization","volume":"83","author":"David","year":"2006","journal-title":"Optom. Vis. Sci."},{"key":"B6","volume-title":"Summary of Product character-istics. Lucentis 10 mg\/mL Solution for Injection","year":"2016"},{"key":"B7","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/s0161-6420(95)30968-2","article-title":"The natural history of idiopathic subfoveal choroidal neovascularization","volume":"102","author":"Ho","year":"1995","journal-title":"Ophthalmology"},{"key":"B8","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s10633-020-09812-w","article-title":"ISCEV standard for clinical multifocal electroretinography (MfERG) (2021 update)","volume":"142","author":"Hoffmann","year":"2021","journal-title":"Doc. Ophthalmol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"6644691","DOI":"10.1155\/2021\/6644691","article-title":"Multifocal electroretinogram can detect the abnormal retinal change in early stage of Type2 DM patients without apparent diabetic retinopathy","volume":"2021","author":"Huang","year":"2021","journal-title":"J. Diabetes Res."},{"key":"B10","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1097\/IAE.0b013e3181c9699c","article-title":"Results of 1-year follow-up examinations after intravitreal bevacizumab administration for idiopathic choroidal neovascularization","volume":"30","author":"Inoue","year":"2010","journal-title":"Retina"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1016\/j.ophtha.2014.01.034","article-title":"Quantitative optical coherence tomography angiography of choroidal neovascularization in age-related macular degeneration","volume":"121","author":"Jia","year":"2014","journal-title":"Ophthalmology"},{"key":"B12","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1046\/j.1600-0420.2004.00217.x","article-title":"Transpupillary thermotherapy for idiopathic subfoveal choroidal neovascularization","volume":"82","author":"Kumar","year":"2004","journal-title":"Acta Ophthalmol. Scand."},{"key":"B13","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.ajo.2018.08.026","article-title":"Conbercept for treatment of neovascular age-related macular degeneration: results of the randomized phase 3 PHOENIX study","volume":"197","author":"Kun","year":"2019","journal-title":"Am. J. Ophthalmol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1097\/IAE.0000000000001744","article-title":"Efficacy and safety of ranibizumab for the treatment of choroidal neovascularization due to uncommon cause: twelve-month results of the minerva study","volume":"38","author":"Lai","year":"2018","journal-title":"Retina"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1080\/02713683.2017.1285943","article-title":"Comparison of conbercept with ranibizumab for the treatment of macular edema secondary to branch retinal vein occlusion","volume":"42","author":"Li","year":"2017","journal-title":"Curr. Eye Res."},{"key":"B16","doi-asserted-by":"publisher","first-page":"4505","DOI":"10.2147\/IJGM.S365886","article-title":"Morphological and functional features in patients with idiopathic macular hole treatment","volume":"15","author":"Li","year":"2022","journal-title":"Int. J. Gen. Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"95:e3264","DOI":"10.1097\/MD.0000000000003264","article-title":"Optical coherence tomography angiography of pathological myopia sourced and idiopathic choroidal neovascularization with follow-up","volume":"95","author":"Liu","year":"2016","journal-title":"Med. (Baltim)"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.2147\/DDDT.S67536","article-title":"Profile of conbercept in the treatment of neovascular age-related macular degeneration","volume":"9","author":"Lu","year":"2015","journal-title":"Drug Des. Dev. Ther."},{"key":"B19","doi-asserted-by":"publisher","first-page":"720804","DOI":"10.3389\/fmed.2021.720804","article-title":"Efficacy of conbercept in the treatment of choroidal neovascularization secondary to pathologic myopia","volume":"8","author":"Lu","year":"2021","journal-title":"Front. Med. (Lausanne)"},{"key":"B20","doi-asserted-by":"publisher","first-page":"4664","DOI":"10.1167\/iovs.07-1360","article-title":"Long-term follow-up of retinitis pigmentosa patients with multifocal electroretinography","volume":"49","author":"Nagy","year":"2008","journal-title":"Invest Ophthalmol. Vis. Sci."},{"key":"B21","doi-asserted-by":"publisher","first-page":"5367","DOI":"10.2147\/DDDT.S477677","article-title":"Effects of dexamethasone intravitreal implant on multifocal electroretinography in diabetic macular oedema","volume":"18","author":"Paris","year":"2024","journal-title":"Drug Des. Devel Ther."},{"key":"B22","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1139\/i10-019","article-title":"Outcome of intravitreal bevacizumab for idiopathic choroidal neovascularization in the Chinese population","volume":"45","author":"Qi","year":"2010","journal-title":"Can. J. Ophthalmol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.3760\/cma.j.issn.0366-6999.20140544","article-title":"Intravitreal ranibizumab therapy versus photodynamic therapy for idiopathic choroidal neovascularization: a comparative study on visual acuity, retinal and choroidal thickness","volume":"127","author":"Shi","year":"2014","journal-title":"Chin. Med. J. (Engl)"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1097\/IAE.0000000000000491","article-title":"Anti-vascular endothelial growth factor therapy for naive idiopathic choroidal neovascularization: a comparative study","volume":"35","author":"Sudhalkar","year":"2015","journal-title":"Retina"},{"key":"B25","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s12886-020-01390-4","article-title":"Evaluation of efficacy and recurrence for anti-vascular endothelial growth factor therapy in idiopathic choroidal neovascularization","volume":"20","author":"Wu","year":"","journal-title":"BMC Ophthalmol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1089\/jop.2019.0075","article-title":"Long-term efficacy of intravitreal conbercept injection in the treatment of idiopathic choroidal neovascularization","volume":"36","author":"Wu","year":"","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"B27","doi-asserted-by":"publisher","first-page":"390","DOI":"10.3109\/09273948.2010.483315","article-title":"Serum inflammatory factors in patients with idiopathic choroidal neovascularization","volume":"18","author":"Yang","year":"2010","journal-title":"Ocul. Immunol. Inflamm."},{"key":"B28","doi-asserted-by":"publisher","first-page":"31880","DOI":"10.1038\/srep31880","article-title":"Idiopathic choroidal neovascularization: intraocular inflammatory cytokines and the effect of intravitreal ranibizumab treatment","volume":"6","author":"Yin","year":"2016","journal-title":"Sci. Rep."},{"key":"B29","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.ophtha.2010.08.008","article-title":"A phase 1 study of KH902, a vascular endothelial growth factor receptor decoy, for exudative age-related macular degeneration","volume":"118","author":"Zhang","year":"2011","journal-title":"Ophthalmology"},{"key":"B30","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.ajo.2011.07.019","article-title":"Intravitreal bevacizumab for treatment of subfoveal idiopathic choroidal neovascularization: results of a 1-year prospective trial","volume":"153","author":"Zhang","year":"2012","journal-title":"Am. J. Ophthalmol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1007\/s10792-021-01737-w","article-title":"Impacts of intravitreal anti-VEGF therapy on retinal anatomy and neurophysiology in diabetic macular edema","volume":"41","author":"Z\u00fcbeyir","year":"2021","journal-title":"Int. Ophthalmol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1854440\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T04:49:31Z","timestamp":1782276571000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1854440\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,24]]},"references-count":31,"alternative-id":["10.3389\/fphar.2026.1854440"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1854440","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,24]]},"article-number":"1854440"}}